The C-Band Alliance, which includes Intelsat (I), SES, Eutelsat (EUTLF) and Telesat announced that up to 200 MHz of mid-band spectrum could be cleared, dependent upon demand, under its updated proposal to the U.S. Federal Communications Commission opening new spectrum to support 5G wireless deployment while protecting current users. This updated commitment will be reflected in comment filings due October 29 under the FCC Notice of Proposed Rule Making proceeding. The proposal increases by 80% the amount of spectrum that could be made available for 5G terrestrial use as compared to the initial proposal made by Intelsat and SES. This announcement allows the CBA and its members to engage in detailed planning of the complicated task of moving customers to different frequency assignments, facilitated through new satellite capacity and innovative technical solutions, implementing new ground infrastructure and modifying the significant existing infrastructure deployed nationwide.

BNY Mellon and Bank of the West announced agreement today where BNY Mellon is providing Bank of the West extended capabilities to help deliver faster payments solutions for its commercial clients through connectivity to RTP and Disbursements with Zelle. "This reseller agreement is part of our strategy to help banks accelerate payment innovation," said Tony Brady, Digital Platform Officer for BNY Mellon's Treasury Services business. "In turn, banks can 'pay it forward' to their clients. It's part of the responsibility we take on as a leader in modernizing the global payment ecosystem."

AbbVie announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis. After 8 weeks, upadacitinib (15/30/45 mg, once daily) met the primary endpoint of clinical remission and all ranked secondary endpoints. These clinical data, in addition to patient-reported outcomes data from the study, are being presented at United European Gastroenterology Week 2018 in Vienna, Austria. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established. The study showed that significantly more patients achieved clinical remission with upadacitinib (14/14/20 percent of patients in the 15/30/45 mg groups) compared to placebo (0 percent) at week 8.1 Additionally, key secondary endpoints were also achieved at week 8 across the upadacitinib 15/30/45 mg groups, including endoscopic improvement, clinical remission and clinical response. The upadacitinib 7.5 mg group did not meet the primary endpoint. These results are being presented October 22 during an oral presentation entitled "Efficacy and safety of upadacitinib as an induction therapy for patients with moderately to severely active ulcerative colitis: data from the phase 2b study U-ACHIEVE" from 2:12 - 2:24 p.m. CEST.